Regulatory Affairs Dynamic

A specialized skill for regulatory affairs leadership in HealthTech and MedTech — covering global regulatory strategy, submission planning, regulatory intelligence, cross-functional coordination, and multi-market registration for medical devices and health technologies.

When to Use This Skill

Choose Regulatory Affairs Dynamic when you need to:

• Develop global regulatory strategies for medical device launches
• Plan and coordinate regulatory submissions across multiple markets
• Navigate regulatory pathway selection (510(k), De Novo, PMA, CE Mark)
• Track regulatory intelligence and assess impact of new regulations
• Coordinate cross-functional teams for submission readiness

Consider alternatives when:

• You need detailed FDA submission preparation (use an FDA skill)
• You need EU MDR technical documentation (use an MDR skill)
• You need quality system implementation (use a QMS skill)

Quick Start

Copy
# Create a global regulatory strategy
claude "Develop a regulatory strategy for launching a Class II cardiac monitoring wearable in the US, EU, Canada, and Japan. Include pathway selection, timeline, and key milestones."

Copy
# Global Regulatory Strategy
## Device: Cardiac Monitoring Wearable (Class II)

## Market Entry Sequence
1. **US (FDA)** — Lead market (largest, best predicate landscape)
2. **EU (MDR)** — Parallel with US (long NB timelines)
3. **Canada (Health Canada)** — Follows US clearance
4. **Japan (PMDA)** — Follows US + additional clinical data

## Regulatory Pathways by Market

| Market    | Pathway      | Classification | Timeline    |
|-----------|-------------|----------------|-------------|
| US        | 510(k)      | Class II       | 6-9 months  |
| EU        | MDR Annex IX| Class IIa      | 12-18 months|
| Canada    | Class II license| Class II   | 4-6 months  |
| Japan     | PMDA Shonin | Class II       | 12-14 months|

## Key Milestones

### Phase 1: Preparation (Months 1-3)
- Finalize intended use / indications
- US predicate search and selection
- EU classification confirmation
- Pre-submission meetings (FDA Q-Sub, NB)
- Clinical evidence gap analysis

### Phase 2: Submission Development (Months 4-9)
- 510(k) submission preparation
- MDR technical documentation (Annex II/III)
- Clinical evaluation report
- Software documentation (IEC 62304)
- Biocompatibility testing (ISO 10993)

### Phase 3: Regulatory Review (Months 9-18)
- FDA 510(k) review (90-180 days)
- NB conformity assessment (6-12 months)
- Additional Information responses
- Health Canada application (post-US clearance)
- PMDA consultation and submission

### Phase 4: Market Authorization (Months 15-24)
- FDA clearance → US market entry
- CE marking → EU market entry
- Health Canada license → Canadian market
- PMDA approval → Japan market entry

Core Concepts

Regulatory Pathway Comparison

Factor	FDA 510(k)	EU MDR CE	Health Canada	Japan PMDA
Basis	Predicate equiv	Essential req	Safety & efficacy	Approval system
Clinical data	Often exempt	CER required	Varies	Required
Review time	90-180 days	6-18 months	60-75 days	12-14 months
Annual renewal	No (listing)	Certificate renewal	Annual license	No (post-mkt)
Post-market	MDR/MedWatch	PMS/PSUR/PMCF	Problem reports	PMDA reporting

Regulatory Submission Planning

Copy
## Submission Readiness Checklist

### Regulatory Intelligence
- [ ] Applicable regulations identified per market
- [ ] Applicable standards mapped (harmonized + local)
- [ ] Predicate/equivalent device analysis complete
- [ ] Regulatory guidance documents reviewed

### Technical Documentation
- [ ] Device description and specifications
- [ ] Design and manufacturing information
- [ ] Risk management file (ISO 14971)
- [ ] Verification and validation reports
- [ ] Clinical evidence package
- [ ] Software documentation (if SaMD/SiMD)
- [ ] Labeling and IFU

### Administrative
- [ ] Regulatory agent appointed (where required)
- [ ] Establishment registration current
- [ ] UDI assignment and GUDID registration
- [ ] Fees calculated and payment authorized

### Team Readiness
- [ ] Cross-functional review of submission
- [ ] Response team identified for questions
- [ ] Post-clearance activities planned

Regulatory Intelligence Tracking

Copy
## Regulatory Watch Items

### Active Monitoring Sources
- FDA Federal Register notices
- EU Official Journal + MDCG guidance
- Health Canada medical device recalls and alerts
- IMDRF harmonization documents
- PMDA notifications and guidance

### Change Impact Assessment Template
| Change                  | Impact    | Action Required         | Deadline   |
|------------------------|-----------|------------------------|------------|
| FDA QMSR final rule    | High      | Gap assessment, update QMS| TBD      |
| MDR Annex XVI deadline | Medium    | Reclassify aesthetic devices| 2025-06 |
| ISO 14971:2019 adopted | Low       | Already compliant       | —          |

Configuration

Parameter	Description	Example
target_markets	Markets for regulatory strategy	["US", "EU", "Canada"]
device_class	Primary device classification	"Class II"
device_type	Type of medical device	"cardiac wearable"
has_software	Device contains software	true
submission_type	Primary submission pathway	"510k"
output_format	Strategy document format	"markdown" / "pptx"

Best Practices

1. Select the lead market based on strategic advantage, not geography — The US often provides the fastest pathway for Class II devices with good predicates. EU MDR timelines are longer but may be required for revenue. Sequence markets to leverage one clearance to accelerate the next.

2. Engage regulatory authorities early through pre-submission meetings — FDA Q-Subs, EU Notified Body consultations, and PMDA consultations cost time but save months of back-and-forth during formal review. Regulators' written feedback is binding on them and reduces submission risk.

3. Build a single technical file that serves multiple markets — Rather than creating separate documentation packages for each market, build a comprehensive technical file that meets the strictest requirements, then extract market-specific submissions from it. This reduces duplication and inconsistency.

4. Track regulatory commitments in a central register — Post-clearance commitments (post-market studies, PSUR submissions, annual reports) accumulate across markets. A missed commitment can jeopardize your registration. Maintain a single register with owners, deadlines, and status.

5. Anticipate Additional Information requests and prepare responses proactively — Review common AI/additional information requests for your device type by searching FDA's MAUDE database and similar resources. Prepare supporting data for likely questions before submission to reduce review cycles.

Common Issues

Regulatory strategy is developed too late in the development cycle — Teams design the device first, then ask "how do we get this cleared?" Design decisions made without regulatory input (materials, claims, labeling) may require expensive changes. Embed regulatory affairs in the design process from concept phase.

Clinical evidence strategy doesn't match regulatory requirements — The clinical evidence needed for FDA 510(k) (often bench testing and predicate equivalence) differs significantly from EU MDR (clinical evaluation report with PMCF plan). A single clinical strategy that satisfies one market may leave gaps for another.

Post-market obligations are understaffed — Organizations invest heavily in getting devices cleared but understaff post-market activities. PSURs, vigilance reporting, PMCF studies, and complaint trend analysis require ongoing resources. Budget for post-market compliance as a permanent cost, not a one-time project.